{{Rsnum
|rsid=10498792
|Gene=PKHD1
|Chromosome=6
|position=51801833
|Orientation=plus
|GMAF=0.1625
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PKHD1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 1.8 | 20.4 | 77.9
| HCB | 2.9 | 30.7 | 66.4
| JPT | 2.7 | 19.5 | 77.9
| YRI | 4.1 | 41.5 | 54.4
| ASW | 7.0 | 45.6 | 47.4
| CHB | 2.9 | 30.7 | 66.4
| CHD | 1.9 | 23.1 | 75.0
| GIH | 1.0 | 10.9 | 88.1
| LWK | 6.4 | 44.5 | 49.1
| MEX | 0.0 | 19.0 | 81.0
| MKK | 3.8 | 38.5 | 57.7
| TSI | 0.0 | 15.7 | 84.3
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs10498792
|PubMedID=17903305
|Condition=Prostate cancer
|Gene=PKHD1
|Risk Allele=
|pValue=3.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs10498792
|Name_s=
|Gene_s=PKHD1
|Feature=
|Evidence=PubMed ID:17903305; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356385
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10498792
|overall_frequency_n=17
|overall_frequency_d=128
|overall_frequency=0.132812
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=14
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}